Amgen launches Humira biosimilar, releases Q4 earnings report

Amgen made two major announcements Tuesday by launching its Humira biosimilar and releasing its most recent quarterly earnings report.

Amjevita, the first biosimilar to AbbVie’s blockbuster drug Humira, is now available in the U.S. at two different price points. Amjevita is available at a list price 55% below the current Humira list price as well as at a list price 5% below the Humira list price.